Welcome to our dedicated page for Predictive Oncology SEC filings (Ticker: POAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Predictive Oncology Inc. (NASDAQ: POAI), which is changing its name to Axe Compute Inc. with an expected ticker change to AGPU, provides access to the company’s official regulatory disclosures. These documents include current reports on Form 8‑K, proxy statements, and other filings that describe material events, governance decisions, financing transactions, and listing matters.
Recent Form 8‑K filings detail several key developments. One 8‑K reports the adoption of a digital asset treasury strategy supported by private placements involving cash and in‑kind contributions of ATH, the native utility token of the Aethir ecosystem. Other 8‑Ks describe the launch and terms of these private placements, related registration rights agreements, and the use of proceeds to acquire ATH and support working capital and general corporate purposes. Additional 8‑Ks cover the 1‑for‑15 reverse stock split of the company’s common stock, actions taken to address Nasdaq listing requirements, and the company’s belief that it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement.
The filings also document corporate governance and shareholder matters. A definitive proxy statement on Schedule DEF 14A outlines proposals for the annual meeting, including the election of directors, ratification of the independent auditor, amendments to the 2024 Equity Incentive Plan, approval of the issuance of shares upon exercise of pre‑funded warrants, and a non‑binding advisory vote on executive compensation. Another 8‑K describes shareholder approval of these items and the resulting increase in shares available under the equity plan.
One notable 8‑K filing reports the corporate name change from Predictive Oncology Inc. to Axe Compute Inc., effective December 11, 2025, and states that the Nasdaq ticker symbol is expected to change from POAI to AGPU on or about December 12, 2025. The filing notes that outstanding stock certificates remain valid and that the CUSIP number for the common stock will not change in connection with the name change.
Through Stock Titan, users can review these SEC filings in sequence and, with AI‑powered summaries, quickly understand the implications of complex documents such as 8‑Ks, proxy statements, and registration‑related supplements. This includes identifying how financing structures, equity plans, reverse splits, and digital asset strategies affect the company’s capital structure and governance over time.
Predictive Oncology Inc. (POAI) reports that it believes it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. The company cites stockholders’ equity in excess of $2.5 million following the closing of two private investment in public equity (PIPE) transactions on October 7, 2025. These PIPE deals provided an aggregate of approximately $343.5 million, including about $50.8 million in cash and approximately $292.7 million in notional value of in-kind contributions of certain crypto assets, which the company states represent a discounted value of about $173.3 million. This capital and asset infusion is the basis for the company’s view that it satisfies Nasdaq Listing Rule 5550(b)(1).
Predictive Oncology Inc. is registering the resale of up to 5,970,181 shares of common stock by existing stockholders. These consist of 2,547,789 PIPE Shares issued in August and September 2025 private placements and 3,422,392 shares issuable upon exercise of various warrants, including pre-funded Cash PIPE Warrants, Agent Warrants and Advisor Warrants. The company is not selling any new shares in this offering and will not receive proceeds from stockholder resales, though it may receive cash if warrants are exercised.
The filing also details a major shift in strategy toward a digital asset treasury centered on Aethir tokens (ATH). As of November 19, 2025, the company held about 5.6 billion ATH valued at approximately $107 million, with 3.6 billion tokens locked and 2.0 billion unlocked. Extensive risk disclosures explain that concentrating treasury assets in ATH, using staking, DeFi and third-party asset managers, and operating in an evolving regulatory environment could create significant volatility in earnings, liquidity constraints and potential adverse impacts on the stock price.
Predictive Oncology Inc. announced that it scheduled a conference call and webcast at 9:00 a.m. Eastern Time on November 17, 2025 to discuss its financial results for the third quarter ended September 30, 2025 and to provide an update on its digital asset strategy. The company prepared an investor presentation for this event, which is available on its investor relations page and is furnished as Exhibit 99.1. The furnished materials are provided under Regulation FD and are not treated as filed for liability purposes under the securities laws unless specifically incorporated by reference in another filing.
Predictive Oncology Inc. (POAI) filed its Q3 2025 report, showing a sharp net loss as the company repositioned its strategy and balance sheet. For the quarter ended September 30, revenue was $3,618 and operating loss was $3.28 million. A non-cash loss on derivative instruments of $74,366,000 drove a quarterly net loss of $77,651,843. The derivative relates to a cryptocurrency-linked private placement agreement recorded at fair value.
As of September 30, cash and cash equivalents were $181,667, total assets were $3.14 million, and stockholders’ deficit was $(77.43) million, reflecting a recorded derivative liability of $74,366,000. After quarter-end, on October 7, 2025, the company closed two private placements for approximately $50.8 million in aggregate cash gross proceeds, and believes its working capital will fund operations for at least 12 months. POAI completed a 1‑for‑15 reverse stock split effective September 30, 2025, and subsequently regained compliance with Nasdaq’s minimum bid price rule. As of November 10, 2025, there were 3,393,516 common shares outstanding.
Predictive Oncology Inc. filed a prospectus supplement to its existing S-3 ATM program, updating the amount it may sell under General Instruction I.B.6. As of October 29, 2025, the company may offer and sell common stock with an aggregate offering price of up to $18,330,000 through H.C. Wainwright & Co. as sales agent.
The filing notes the I.B.6 framework, allowing primary offerings up to one-third of public float and removal of this limit if public float exceeds $75.0 million. It also states that approximately $2,417,337 of securities were sold under I.B.6 during the prior 12 months.
Predictive Oncology (POAI) filed a prospectus supplement for an at-the-market offering of up to $18,330,000 of common stock under its agreement with H.C. Wainwright, subject to General Instruction I.B.6 limits.
Over the last 12 months, the company sold 139,680 shares for aggregate gross proceeds of approximately $1,872,333 through the ATM. As calculated within 60 days of this supplement, public float was $62,257,699, based on 3,458,934 non‑affiliate shares at $17.9991. The company noted $2,417,337 of securities sold pursuant to I.B.6 in the same period. If public float rises above $75.0 million, the I.B.6 cap would no longer apply; additional capacity would be reflected in a future supplement.
As of October 28, 2025, the company held approximately 5.49 billion Aethir tokens valued at about $159.2 million based on a $0.0290 price.
Predictive Oncology Inc. (POAI) set its Annual Meeting for November 25, 2025 to vote on key items including board elections, auditor ratification, equity plan changes, and a large share issuance tied to pre-funded warrants. Stockholders of record as of October 24, 2025 (3,501,430 shares outstanding) may vote.
The ballot seeks: (1) election of two Class I directors; (2) ratification of KPMG as independent auditor for fiscal 2025; (3) an amendment to the 2024 Equity Incentive Plan to lift the reserve from 66,667 to 1,066,667 shares and cap incentive stock options at 500,000; (4) approval, under Nasdaq Listing Rule 5635(a), of the issuance of 14,903,393 shares of common stock upon exercise of pre-funded warrants to purchase an equal number of shares; and (5) a non-binding say‑on‑pay vote.
The company notes an overhang of 1.5% as of October 13, 2025, which would rise to approximately 24% if the plan amendment to 1,066,667 shares is approved, before any additional shares from pre-funded warrant exercises. A quorum requires 1,167,144 shares present or represented by proxy.
Predictive Oncology Inc. filed a resale registration covering up to 5,970,181 shares of common stock, to be sold from time to time by the selling stockholders after effectiveness. The company is not offering any shares.
The registered amount includes 3,365,690 PIPE Shares issued in August and September private placements, plus 2,604,491 shares issuable upon warrant exercise, consisting of 1,037,250 Cash PIPE Warrant Shares, 218,335 Agent Warrant Shares, and 1,348,906 Advisor Warrant Shares.
No proceeds will go to the company from stockholder resales. The company would receive cash only upon warrant exercises. The Cash PIPE Warrants carry a nominal $0.01 per-share exercise price; Agent and Advisor Warrants are exercisable at $11.6265 per share. POAI trades on Nasdaq; the last reported price was $9.30 per share on October 21, 2025.
Predictive Oncology Inc. filed a resale registration covering up to 14,903,393 shares of common stock underlying pre-funded warrants issued under a September 29, 2025 securities purchase agreement. The shares may be sold from time to time by the selling stockholders named in the prospectus.
The company is not offering any shares and will not receive proceeds from sales by the selling stockholders; it would receive only any cash paid upon warrant exercise. The warrants carry a $0.01 per share exercise price, have no expiration, and include a 19.99% beneficial ownership limitation. Exercise of these warrants is subject to shareholder approval for the underlying share issuance.
As context, the company’s Nasdaq ticker is POAI, and the last reported sale price was $9.30 per share on October 21, 2025. The filing notes a recent 1-for-15 reverse stock split effective September 30, 2025, and outlines a separate cash PIPE and a crypto-funded PIPE that introduced these pre-funded warrants. The plan of distribution permits various sale methods by the selling holders.